| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001673 | EBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10013297 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10004489 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10018843 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10017715 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10004413 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10006422 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10030760 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10030761 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
| TVIS10039253 | HBV | ENSG00000048052.25 | protein_coding | HDAC9 | No | No | 9734 | B7Z3P7 Q9UKV0 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HDAC9 |
|---|---|
| DrugBank ID | DB00313 |
| Drug Name | Valproic acid |
| Target ID | BE0000881 |
| UniProt ID | Q9UKV0 |
| Regulation Type | inhibitor |
| PubMed IDs | 15166525; 15242819; 15289798; 15685243; 15850602; 17514356; 20811699 |
| Citations | Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM: Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS. 2004 May 21;18(8):1101-8.@@Michaelis M, Kohler N, Reinisch A, Eikel D, Gravemann U, Doerr HW, Nau H, Cinatl J Jr: Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid. Biochem Pharmacol. 2004 Aug 1;68(3):531-8.@@Kanai H, Sawa A, Chen RW, Leeds P, Chuang DM: Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J. 2004;4(5):336-44.@@Stockhausen MT, Sjolund J, Manetopoulos C, Axelson H: Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):751-9.@@Beutler AS, Li S, Nicol R, Walsh MJ: Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 2005 May 13;76(26):3107-15.@@Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007 Aug;64(16):2090-103.@@Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T, Ida H, Agata N, Yamada H: Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int J Oncol. 2010 Oct;37(4):787-95. |
| Groups | Approved; Investigational |
| Direct Classification | Methyl-branched fatty acids |
| SMILES | CCCC(CCC)C(O)=O |
| Pathways | Valproic Acid Metabolism Pathway |
| PharmGKB | PA451846 |
| ChEMBL | CHEMBL109 |
